Search research articles
Contact Us
Filters
Showing results (111-120 of 139) with videos related to
Page
of 14
Sort By:
ESMO Open
|
June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2021
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
A Laparra, M Kfoury, S Champiat, et al.
ESMO Open
|
November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50
A De Giglio, L Zullo, A Di Federico, et al.
Molecular Cancer
|
November 13, 2024
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<sup>G12D</sup>-driven non-small cell lung cancer
W J McDaid, L Wilson, H Adderley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
ESMO Open
|
December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
C Leduc, J P Merlio, B Besse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
B Besse, J Mazières, L Ribassin-Majed, et al.
Clinical Lung Cancer
|
March 19, 2021
RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection
C Basse, A Botticella, T J Molina, et al.
ESMO Open
|
March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
N Girard, S Galland-Girodet, V Avrillon, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 139) with videos related to
Sort By:
Page
of 14
ESMO Open
|
June 22, 2026
Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC)
C Parisi, M Banini, F Mantuano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 18, 2021
Multiple immune-related toxicities in cancer patients treated with anti-programmed cell death protein 1 immunotherapies: a new surrogate marker for clinical trials?
A Laparra, M Kfoury, S Champiat, et al.
ESMO Open
|
November 18, 2025
Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50
A De Giglio, L Zullo, A Di Federico, et al.
Molecular Cancer
|
November 13, 2024
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<sup>G12D</sup>-driven non-small cell lung cancer
W J McDaid, L Wilson, H Adderley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 20, 2021
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y Loriot, A Marabelle, J P Guégan, et al.
ESMO Open
|
December 25, 2021
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier, B Besse, F Barlesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program
C Leduc, J P Merlio, B Besse, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
B Besse, J Mazières, L Ribassin-Majed, et al.
Clinical Lung Cancer
|
March 19, 2021
RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection
C Basse, A Botticella, T J Molina, et al.
ESMO Open
|
March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
N Girard, S Galland-Girodet, V Avrillon, et al.
Page
of 14